Drug intelligence / Profile preview

OPC-13015

Development stage: Preclinical
Lead developer: Otsuka Holdings
Modality: Small Molecules

Overview

OPC-13015 is an *active metabolite* of cilostazol, known chemically as 3,4-dehydro cilostazol. It exhibits a **stronger inhibitory effect** on **type 3 phosphodiesterase (PDE3)** than its parent drug cilostazol, with reports indicating an inhibitory effect approximately five times greater. OPC-13015 is produced in vivo following cilostazol administration. Recent studies have examined the relationship between blood levels of OPC-13015 and cognitive outcomes in patients treated with cilostazol for mild cognitive impairment or Alzheimer's disease, suggesting that higher OPC-13015 exposure correlates with preservation of cognitive function and may serve as a predictive biomarker for cilostazol efficacy in Alzheimer's disease.

Other names: 3,4-dehydro cilostazol

Targets

PDE3

Beyond the preview

Go deeper on OPC-13015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OPC-13015.

Explore the full profile